Charged multivesicular body protein 5 (CHMP5) has a key role in multivesicular body biogenesis and a critical role in the downregulation of signaling pathways through receptor degradation. However, the role of CHMP5 in T-cell receptor (TCR)-mediated signaling has not been previously investigated. In this study, we utilized a short hairpin RNA-based RNA interference approach to investigate the functional role of CHMP5. Upon TCR stimulation, CHMP5-knockdown (CHMP5 KD ) Jurkat T cells exhibited activation of TCR downstream signaling molecules, such as PKCθ and IKKαβ, and resulted in the activation of nuclear factor-κB and the marked upregulation of TCR-induced gene expression. Moreover, we found that activator protein-1 and nuclear factor of activated T-cells transcriptional factors were markedly activated in CHMP5 KD Jurkat cells in response to TCR stimulation, which led to a significant increase in interleukin-2 secretion. Biochemical studies revealed that CHMP5 endogenously forms high-molecular-weight complexes, including TCR molecules, and specifically interacts with TCRβ. Interestingly, flow cytometry analysis also revealed that CHMP5 KD Jurkat T cells exhibit upregulation of TCR expression on the cell surface compared with control Jurkat T cells. Taken together, these findings demonstrated that CHMP5 might be involved in the homeostatic regulation of TCR on the cell surface, presumably through TCR recycling or degradation. Thus CHMP5 is implicated in TCR-mediated signaling.
INTRODUCTION
Charged multivesicular body protein 5 (CHMP5) is a coiled protein homologous to the yeast Vps60/Mos10 gene and other endosomal sorting complexes required for transport (ESCRT)-III complex members, which are responsible for the final conversion of late endosomal multivesicular body (MVB) to lysosomes. 1, 2 MVB is a special type of late endosome and a crucial intermediate in the internalization of nutrients, ligands and receptors via the endolysosomal system; therefore, MVB has a crucial role in sorting membrane proteins destined for degradation or routing to the lysosome. [3] [4] [5] [6] [7] It is well established that the degradation of cell surface receptors through endocytosis is a common mechanism for the downregulation of growth factor and TGFβ (transforming growth factor β) receptor signaling. 3 A previous study has shown that CHMP5 is required for the downregulation of TGFβ signaling pathways via the lysosomal degradation of internalized receptors. 2 These results suggest that CHMP5 may have a key role in the regulation of signaling pathways via receptor downregulation.
CHMP5 downregulates signaling pathways through receptor degradation. 1,2 Therefore, we determined whether CHMP5 is involved in TCR-mediated signaling via TCR modulation. In this study, we utilized a short hairpin RNA (shRNA)-based RNA interference approach to generate CHMP5-knockdown (CHMP5 KD ) Jurkat T cells. Our data demonstrated that, upon TCR stimulation, CHMP5 KD Jurkat T cells exhibit a marked augmentation of TCR-mediated signaling with regard to the activation of three transcriptional factors (nuclear factor (NF)-κB, activator protein 1 (AP-1) and nuclear factor of activated T-cells (NFAT)), leading to the upregulation of TCR-induced genes and interleukin (IL)-2 secretion. Furthermore, biochemical studies revealed that CHMP5 endogenously forms high-molecular-weight complexes, including TCR molecules, and specifically interacted with TCRβ. These results suggested that CHMP5 regulates cell surface TCR expression and is thereby implicated in TCR-mediated signaling.
MATERIALS AND METHODS

Cells and reagents
Jurkat cells were grown in RPMI 1640 media supplemented with 10% fetal bovine serum (Sigma-Aldrich, St Louis, MO, USA), 50 U ml − 1 Figure 1 CHMP5 knockdown enhances TCR-induced signaling, activating NF-κB. (a) Control (Ctrl) and CHMP5 KD Jurkat cells generated by control shRNA lentiviral particles and CHMP5 shRNA lentiviral particles, respectively, were stimulated with anti-CD3/anti-CD28 for different times, as described in Materials and methods section. Cell extracts were analyzed by western blotting for CHMP5, pho-Lck, Lck, pho-ZAP-70, ZAP-70, pho-PKCθ, PKCθ, pho-IKKαβ, IKKα and GAPDH as a loading control. (b, c) Relative pho-PKCθ (b) and pho-IKKαβ (c) levels were evaluated by Image J (lower panels). All error bars represent ± s.d. of the mean from triplicate samples. (d) Control (Ctrl) and CHMP5 KD Jurkat cells were transfected with pBIIx-luc NF-κB-dependent reporter together with the Renilla luciferase vector. After 36 h, cells were stimulated with anti-CD3/anti-CD28 at different times and a luciferase assay was performed. All error bars represent ± s.d. of the mean from triplicate samples. *Po0.01. (e, f) Ctrl and CHMP5 KD Jurkat cells were stimulated with anti-CD3/anti-CD28 for different times or PMA as a positive control. Nuclear extracts were prepared and analyzed for p65 (e) and p50 (f) binding to an NF-κB consensus oligonucleotide. All error bars represent ± s.d. of the mean from triplicate samples. *Po0.01 and **Po0.05.
penicillin and 50 μg ml − 1 streptomycin at 37°C in an atmosphere of 5% CO 2 /95% air. Jurkat T cells were infected with control shRNA lentiviral particles (sc-108080, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or CHMP5 shRNA (h) lentiviral particles (sc-60374-V, Santa Cruz) and selected based on the manufacturer's protocols. Control (Ctrl) Jurkat and CHMP5 KD Jurkat cells were maintained and grown in RPMI 1640 media supplemented with 10% fetal bovine serum (Sigma-Aldrich), 50 U ml − 1 penicillin, 4-8 μg ml − 1 puromycin and 50 μg ml − 1 streptomycin at 37°C in an atmosphere of 5% CO 2 /95% air. The antibodies used were anti-CHMP5 (Abcam, Cambridge, CO, USA), anti-GAPDH (Santa Cruz Biotechnology), anti-TCRαβ (BD Biosciences, San Jose, CA, USA), anti-CD3 (BioLegend, San Diego, CA, USA), anti-CD28 (BioLegend), anti-TCRβ (Abcam), anti-pho-PKCθ (Cell Signaling Technology, Danvers, MA, USA), anti-PKCθ (Cell Signaling Technology), anti-pho-IKKαβ (Cell Signaling Technology), anti-IKKα (Cell Signaling Technology), antipho-ZAP-70 (Santa Cruz Biotechnology), anti-ZAP-70 (Santa Cruz Biotechnology), anti-pho-Lck (Santa Cruz Biotechnology) and antiLck (Santa Cruz Biotechnology).
Immunofluorescence microscopy and flow cytometry analyses
Control or CHMP5 KD Jurkat cells were stained with control Ig or phycoerythrin (PE)-conjugated TCR antibody, washed with phosphate-buffered saline and analyzed by flow cytometry (FACSCalibur, BD). 15 For immunofluorescence microscopy analysis, control or CHMP5 KD Jurkat cells were stained with PE-conjugated TCR antibody and washed with phosphate-buffered saline. Cells were imaged on a Zeiss LSM 710 laser-scanning confocal microscope (Carl Zeiss, Jena, Germany). 16 For intracellular IL-2 staining, control or CHMP5 KD Jurkat cells were either treated or not treated with anti-CD3 (10 μg ml − 1 ) and anti-CD28 (5 μg ml − 1 ) antibodies, together with 5 μg of goat anti-mouse immunoglobulin G (IgG) antibody per ml (Signal Transduction Laboratories, Lexington, KY, USA) for 18 h. Intracellular staining for IL-2 with anti-PE-conjugated IL-2 antibody was performed with reagents from Pharmingen Inc. (San Diego, CA, USA) according to the manufacturer's protocol. Cells were analyzed with flow cytometry (FACSCalibur, BD). For the analysis, cell debris was excluded on the forward scatter (FSC) and side scatter (SSC) dot plot panels by using the gating method; IL-2-expressing cells stained with PE-conjugated IL-2 antibodies were then further gated on the FL-2 (PE-IL-2) and FL-1 (auto-fluorescence) dot plot panels.
Gel filtration chromatography
The S-100 fraction from Jurkat T cells was loaded onto a Superose6 10/300 GL column pre-equilibrated with buffer A plus 0.1% Chaps and 0.01% Brij35. The proteins were eluted at 0.3 ml min − 1 as previously described. [16] [17] [18] [19] Samples were analyzed by western blotting using antibodies specific for CHMP5 and TCRβ. 
Immunoblotting (IB) and immunoprecipitation (IP)
Control and CHMP5 KD Jurkat cells were either treated or not treated with anti-CD3 (10 μg ml − 1 ) and anti-CD28 (5 μg ml − 1 ) antibodies, together with 5 μg of goat anti-mouse IgG antibody per ml at different times. Samples were analyzed by western blotting using the indicated antibodies as previously described. [16] [17] [18] [19] For the endogenous IP assay, cell lysates from Jurkat T cells were treated with control IgG or anti-CHMP5 antibodies; the IP assay was then performed, as previously described. [16] [17] [18] [19] Samples were analyzed by western blotting using antibodies specific for CHMP5 and TCRβ.
Luciferase reporter assay
Control and CHMP5 KD Jurkat cells were transiently transfected with the pBIIx-luc nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-dependent reporter or AP-1 constructs, together with the Renilla luciferase vector, using the Neon transfection system (Invitrogen, Carlsbad, CA, USA). Cells pretreated in the presence or absence of anti-CD3 (10 μg ml − 1 ) and anti-CD28 (5 μg ml − 1 ) antibodies at different times were treated with 5 μg of goat anti-mouse IgG antibody per ml at different times. Luciferase activities were measured using a dual Luciferase Assay Kit (Promega, Southampton, UK).
p65/p50/c-fos/pho-c-Jun/NFAT DNA-binding assay Control and CHMP5 KD Jurkat cells were treated in the presence or absence of anti-CD3 (10 μg ml − 1 ) and anti-CD28 (5 μg ml − 1 ) antibodies together with 5 μg of goat anti-mouse IgG antibody per ml at different times. Nuclear proteins were prepared with a CelLytic NuCLEAR Extraction Kit (Sigma-Aldrich) in accordance with the manufacturer's protocol. P65/p50/c-fos/pho-c-Jun/NFAT transcription factor activities were determined using transcription factor assay kits (Active Motif, Carlsbad, CA, USA) according to the manufacturer's instructions.
Enzyme-linked immunosorbent assay (ELISA)
Control and CHMP5 KD Jurkat cells were stimulated with or without anti-CD3 (10 μg ml − 1 ) and anti-CD28 (5 μg ml − 1 ) antibodies, together with 5 μg of goat anti-mouse IgG antibody per ml for 24 h. IL-2 secreted in the culture supernatant was measured using ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Quantitative reverse trnscriptase-PCR (qRT-PCR) analysis
Total RNA was isolated and cDNA was synthesized following the manufacturer's protocol (Qiagen, Valencia, CA, USA). All primers were purchased from Qiagen: CD69 ( 
Microarray analysis
Control and CHMP5 KD Jurkat cells were treated in the presence or absence of anti-CD3 (10 μg ml − 1 ) and anti-CD28 (5 μg ml − 1 ) antibodies together with 5 μg of goat anti-mouse IgG antibody per ml at different times. Total RNA was extracted using TRIzol (Invitrogen) and purified using RNeasy columns (Qiagen,) according to the manufacturer's protocol. Microarray analysis, raw data preparation and statistical analysis was performed as previously described. [20] [21] [22] Statistical analysis
In vitro data are presented as the mean ± s.d. of the mean from triplicate samples. Comparisons were statistically tested using Student's t-test. P values o0.05 or o0.01 were considered to be statistically significant.
RESULTS
CHMP5 knockdown enhances TCR-induced signaling for the activation of NF-κB
To examine the role of CHMP5 in TCR-mediated signaling, we generated CHMP5-knockdown (CHMP5 KD ) Jurkat T cells using a short hairpin RNA-based RNA interference method. Jurkat T cells were transduced with lentiviral particles containing shRNA targeted to human CHMP5 or control shRNA sequences, as described in anti-CD3/CD28 antibodies, followed by the isolation and preparation of RNA for array analysis. Stimulation with TCR in CHMP5 KD Jurkat cells led to the marked upregulation of a number of genes represented on the array compared with TCR-stimulated control Jurkat cells (Supplementary Figure S1) . Genes represented on the array were those associated with T-cell immunity, intracellular signaling or intracellular kinases, and the expression patterns of these genes were compared between control and CHMP5 KD Jurkat cells; it was found that the expression profiles were markedly upregulated in CHMP5 KD cells, whereas this activity was markedly abolished in PMA/I plus CsA-treated cells (Figure 5a , PMA/I and PMA/I+CsA). Upon TCR stimulation, NFAT DNA-binding activity was significantly increased in control Jurkat cells (Figure 5a , open bars); interestingly, this activity was markedly enhanced in CHMP5 KD Jurkat cells (Figure 5a, closed bars) . The activation of NFAT, along with NF-κB and AP-1 transcription factors, is critical for IL-2 expression through Ca 2+ /calcineurin signaling. 23, 24, [26] [27] [28] Therefore, we assessed whether CHMP5 KD Jurkat cells have enhanced IL-2 secretion in response to TCR stimulation. Accordingly, control and CHMP5 KD Jurkat cells were stimulated for 18 h with or without anti-CD3 and anti-CD28 antibodies, and the intracellular IL-2 levels were measured by flow cytometry. The level of intracellular IL-2 was significantly higher in CHMP5 KD Jurkat cells than in control Jurkat cells (Figure 5b , 6 ± 1% versus 2 ± 1%, respectively). Furthermore, ELISA assay revealed that the marked increase of IL-2 secretion could be observed in CHMP5 KD Jurkat cells in response to TCR stimulation compared with that in control Jurkat cells (Figure 5c, closed bars versus open bars) . To determine whether the expression of calcium-related genes is associated with CHMP5 knockdown in response to TCR stimulation, we performed microarray analysis. Control and CHMP5 KD Jurkat cells were treated with anti-CD3/anti-CD28 at different times, as indicated in Figure 5d . Ten different calcium-related genes were identified from the microarray results, and their expression levels were then compared (Figure 5d , CHMP5 KD versus control Jurkat cells). Seven of these calcium-related genes, including FBLN2 and SPOCK2, were significantly upregulated in CHMP5 KD Jurkat cells in response to TCR stimulation ( Figure 5d ); in addition, the results were partly confirmed by qRT-PCR analysis (Figure 5d , right panels). These results suggest that CHMP5 deficiency leads to activation of NF-kB, NFAT and AP-1 transcriptional factors, thereby increasing IL-2 expression in response to TCR stimulation.
CHMP5 is associated with TCR expression on the cell surface Based on the above results, we explored the cellular mechanism in which CHMP5 deficiency is implicated in TCR-mediated signaling. Previous reports showed that CHMP5 is required for ESCRT-III complex members that are responsible for the final conversion of late endosomal MVB to lysosomes and also has a critical role in the downregulation of signaling pathways through receptor degradation. [1] [2] [3] We evaluated the role of CHMP5 in the downregulation of cell surface TCR. We first tested whether CHMP5 protein is associated with the TCR molecule. Cellular complexes were isolated from wild Jurkat T cells by gel filtration. Western blotting analysis was subsequently performed to identify the co-localization of CHMP5 and TCR molecules. Interestingly, several fractions containing CHMP5 were significantly localized with TCRβ ( Figure 6a , fractions 29-32), suggesting that CHMP5 is endogenously associated with TCR molecules. To verify whether this association results in the molecular interaction between CHMP5 and TCR, we further performed an endogenous IP assay. CHMP5 proteins were pulled down in cell lysates derived from wild-type Jurkat cells with anti-CHMP5 or IgG control antibody. As shown in Figure 6b , endogenous CHMP5 proteins significantly co-precipitated with TCRβ, whereas no significant bands could be observed for the control IgG antibody, suggesting that CHMP5 is endogenously associated with TCR molecules through molecular interactions. It has been shown that a putative CHMP5 dominant-negative mutant leads to accumulation of ligand-bound epidermal growth factor receptor and results in a delay in epidermal growth factor receptor degradation. 28 Therefore, we examined whether CHMP5 knockdown in Jurkat cells affects the expression of TCR on the cell surface. Control or CHMP5 KD Jurkat cells were stained with anti-TCRαβ antibody followed by flow cytometry analysis. Interestingly, TCR expression was markedly higher in CHMP5 KD Jurkat cells than in control Jurkat cells (Figure 6c , black line versus green line; black bar versus green bar in right). The results were further confirmed by immunofluorescence microscopic analysis (Figure 6d ). These results demonstrated that CHMP5 is endogenously associated with TCR, meaning its deficiency affects cell surface TCR expression.
DISCUSSION
In this study, we investigated the role of CHMP5 in TCRmediated signaling. To overcome CHMP5 − / − homozygote mice showing embryonic lethality at day 10 (E10), 2 we utilized a shRNA-based RNA interference approach and generated CHMP5-knockdown Jurkat cells to investigate its functional role in T cells. Consistent with previous reports, 1,2 CHMP5 knockdown was accompanied by an accumulation of structures that appeared to be early endosomes and lysosomes compared with control (Supplementary Figure S2) , supporting the concept that CHMP5 is functionally involved in the formation of early endosomes and lysosomes. We also found that CHMP5 KD Jurkat cells exhibited a marked enhancement of TCR-induced transcriptional factors (NF-κB, AP-1 and NFAT), consequently leading to an increase in TCR-dependent gene expression. Moreover, CHMP5 is endogenously associated and interacts with TCR. Interestingly, TCR expression in CHMP5 KD Jurkat T cells accumulated on the surface, strongly demonstrating a role for CHMP5 in the homeostatic regulation of cell surface TCR.
In addition to the previous findings that CHMP5, one of components of the ESCRT-III, is involved in the final conversion of late endosomal MVB to lysosomes and the downregulation of signaling pathways through receptor degradation, 1,2,6,7 recent evidence indicates that CHMP5 modulates apoptosis in neurodegenerative diseases and cancer through changes in ECSRT-III complex. 29, 30 In line with these results, a previous report showed that CHMP5 is involved in programmed cell death in leukemic cells. 9 Furthermore, CHMP5 is implicated in the antiviral mechanism through the prevention of ISGylation of CHMP2A and CHMP6 and in the retroviral release process via the prevention of LIP5 binding to Vps4. 10, 14 These results suggest that CHMP5 has multicellular functions.
On the basis of these results, we propose a current model, shown in Figure 6e . Briefly, CHMP5 is associated with TCR, and the complex may go to either a recycling pathway through early endosomes or to a degradation pathway through late endosomes fused with lysosomes to maintain homeostatic levels of TCR in normal T cells (Figure 6e, left) . However, the TCR recycling process for the maintenance of homeostatic cell surface TCR levels may be affected in CHMP5 KD cells, leading to increased TCR expression on the cell surface. In this study, we found that, upon TCR stimulation, the accumulated TCRs are functionally active and induce the activation of three transcriptional factors (NF-κB, AP-1 and NFAT), resulting in the regulation of target gene expression, including IL-2 (Figure 6e, right) . In conclusion, these results improve our understanding of the precise role of CHMP5 in different cell types.
